)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
GeoVax Labs
GeoVax Labs (GOVX) investor relations material
GeoVax Labs Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary4 Nov, 2026
Company overview and business model
Clinical-stage biotechnology focused on vaccines and immunotherapies for infectious diseases and solid tumors, using proprietary vector platforms.
GEO-MVA is the near-term priority: an MVA vaccine candidate for mpox, smallpox and other poxviruses, with a pivotal Phase 3 trial planned for Q4 2026; Gedeptin completed Phase 1/2, with combination Phase 2 planned for H2 2027.
Strategy centers on clinical advancement, regulatory approval and commercialization through internal development plus selective licensing and partnerships; May 2026 reprioritization focused resources on GEO-MVA and Gedeptin and ended active COVID-19 vaccine development.
Development relies on third-party manufacturers; cGMP GEO-MVA material is ready for late-stage trials, while continuous avian cell-line manufacturing is under development for potential scale-up.
Financial performance and metrics
FY2025 government-contract revenue $2.489 million vs $3.955 million in FY2024; net loss $21.465 million vs $24.992 million.
H1 2026 revenue $0 vs $2.489 million H1 2025; net loss $9.688 million vs $10.727 million.
H1 2026 R&D expense $7.014 million vs $10.084 million H1 2025; FY2025 R&D expense $18.122 million vs $23.714 million FY2024.
Cash and equivalents were $3.143 million and stockholders’ equity $1.761 million at June 30, 2026; auditor reported substantial doubt about going-concern ability.
Existing cash plus potential, discretionary revolving-loan draws was projected to fund operations into December 2026; offering proceeds plus cash were projected to extend runway into Q1 2027.
Use of proceeds and capital allocation
Estimated net proceeds of $4.628 million, assuming all 29,585,798 securities are shares at $0.169, no pre-funded warrants and no overallotment exercise.
Planned uses include GEO-MVA’s Phase 3 trial, R&D, manufacturing, clinical studies, capital expenditures, working capital and general corporate purposes.
Up to $2.5 million may fund marketing and advertising services for financial-community communications; no such service agreements had been entered into as of the prospectus date.
No proceeds are intended for repayment of the revolving loan; management retains broad discretion over allocation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from GeoVax Labs
- Lower losses, but a short cash runway and financing-dependent clinical plans.GOVX
Q3 2026 - Biotech advances late-stage vaccine and cancer therapy but faces cash constraints and Nasdaq risk.GOVXRegistration filing
- Approval sought for warrant share issuance and reverse split to maintain Nasdaq compliance.GOVXProxy filing
- Vote sought on warrant share issuance and reverse split to support Nasdaq compliance.GOVXProxy filing
- GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply.GOVXCorporate presentation
- Net loss narrowed and lead programs advanced, but cash runway and funding risks remain.GOVXQ2 2026
- Expedited vaccine and oncology programs target global supply gaps and major market opportunities.GOVXCorporate presentation
- Next-gen COVID-19 and mpox vaccines advance with major funding and global supply ambitions.GOVXH.C. Wainwright 26th Annual Global Investment Conference 2024
- Q1 2025 revenue rose to $1.6M, but contract loss and cash runway raise going concern risks.GOVXQ1 2025
Next GeoVax Labs earnings date
Q3 202619 Nov, 2026
GeoVax Labs
Next GeoVax Labs earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
GeoVax Labs Inc is a biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer. The company utilizes its proprietary vaccine platforms to target viral and bacterial pathogens, as well as tumor-associated antigens. Its development pipeline includes both preventive and therapeutic candidates undergoing preclinical and clinical testing. GeoVax Labs Inc is headquartered in Smyrna, Georgia, and its shares are listed on the NASDAQ.